Drug Interaction Report

Ranolazine and Encorafenib: Interaction Details

A pharmacist-reviewed analysis of the Ranolazine and Encorafenib interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Ranolazine

Aspruzyo Ranexa
+

Encorafenib

Braftovi Braftovi®
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Contraindicated
These should generally not be used together.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 149 documented Ranolazine interactions, 16 are rated contraindicated — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
theoretical
Severity
Contraindicated

What happens

Increased risk of QT interval prolongation; reduced ranolazine exposure

Interaction Deep Dive

Coadministration of ranolazine (CYP3A4 substrate) and encorafenib (a CYP3A4 inducer) is contraindicated as it may reduce ranolazine exposure. Coadministration may also increase the risk of QT interval prolongation2. Encorafenib is associated with dose-dependent QTc interval prolongation. Avoid coadministration with other medicinal products known to prolong the QT/QTc interval such as ranolazine. Monitor patients who already have or who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, severe or uncontrolled heart failure and those taking other medicinal products associated with QT prolongation. Correct hypokalemia and hypomagnesemia prior to and during encorafenib administration. Withhold encorafenib until QTcF (QT interval corrected per Fridericia formula) less than or equal to 500 ms, resume at reduced dose. If more than one recurrence, permanently discontinue encorafenib. Also, permanently discontinue encorafenib for QTcF more than 500 ms 1.

Why it happens (mechanism)

Additive QT interval prolongation; induction of CYP3A4-mediated metabolism of ranolazine

Common questions

Can I take Ranolazine and Encorafenib together?

Increased risk of QT interval prolongation; reduced ranolazine exposure Always confirm with your pharmacist or prescriber before making any change.

How serious is the Ranolazine and Encorafenib interaction?

It is rated contraindicated. These should generally not be used together.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Ranolazine or Encorafenib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (2)

  1. Product Information: BRAFTOVI(R) oral capsules, encorafenib oral capsules. Array BioPharma Inc (per FDA), Boulder, CO, 2024. DailyMed
  2. Product Information: RANOLAZINE oral extended-release tablets, ranolazine oral extended-release tablets. Viona Pharmaceuticals Inc. (per Dailymed), Cranford, NJ, 2023. DailyMed
Was this write-up helpful?
Ranolazine

Keep reading about Ranolazine

All Ranolazine interactions (149)
Also serious with: Bexarotene Topical Ketoconazole Topical Brivaracetam Injection Brivaracetam
Encorafenib

Keep reading about Encorafenib

All Encorafenib interactions (468) Encorafenib drug information
Also serious with: Piperaquine Posaconazole Pimozide Doravirine
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

Ranolazine + Activated Charcoal American Hellebore Arsenic Cesium Ephedra Grapefruit Sida Cordifolia St. John's Wort + 145 more
Encorafenib + Activated Charcoal American Hellebore Arsenic Cesium Ephedra Grapefruit Sida Cordifolia St. John's Wort + 143 more

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.